<unk>  (USAN; development code LY3002813) is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer’s disease.<unk>  has shown positive results in Eli Lilly and Co.’s first two trials.<unk>  was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer’s disease.<unk> , also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (Aβ), that is produced in the bone marrow. Whilst the cause of Alzheimer’s disease is still unknown, great advances in amyloid pathology has led to a relation between the quantity of Aβ peptides and the development in Alzheimer's disease. Aβ peptides are deposited in the brain and when in excess will bind together to create a protein plaque.<unk>  targets this protein plaque, clearing the excess protein which causes a burden in the brain.
Donanemab
Tafasitamab
Sutimlimab
Naxitamab
Regdanvimab
Atoltivimab
Efgartigimod alfa
Lepra 